Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Despite standard hormonal therapy that targets the androgen receptor (AR) attenuates
prostate cancer (PCa) effectively in the initial stage, the tumor ultimately converts to …

Metastasis has long been understood to lead to the overwhelming majority of cancer-related
deaths. However, our understanding of the metastatic process, and thus our ability to …

During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …

Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

Immune checkpoint blockade has been largely unsuccessful for the treatment of bone
metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial …

Most cancer deaths are due to metastatic dissemination to distant organs. Bone is the most
frequently affected organ in metastatic prostate cancer and a major cause of prostate cancer …

Emerging evidence indicates that metabolic dysregulation drives prostate cancer (PCa)
progression and metastasis. AMP-activated protein kinase (AMPK) is a master regulator of …

Inactivation of phosphatase and tensin homolog (PTEN) is prevalent in human prostate
cancer and causes high-grade adenocarcinoma with a long latency. Cancer-associated …

Liver metastasis (LM) confers poor survival and therapy resistance across cancer types, but
the mechanisms of liver-metastatic organotropism remain unknown. Here, through in vivo …